Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2011

01-07-2011 | Hepatobiliary Tumors

Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages

Authors: Delia D’Avola, MD, Mercedes Iñarrairaegui, MD, PhD, Fernando Pardo, MD, Fernando Rotellar, MD, PhD, Pablo Marti, MD, José I. Bilbao, MD, PhD, Antonio Martinez-Cuesta, MD, Alberto Benito, MD, PhD, Felix Alegre, MD, Erica Mauleón, MD, José I. Herrero, MD, PhD, Jorge Quiroga, MD, PhD, Jesus Prieto, MD, PhD, Bruno Sangro, MD, PhD

Published in: Annals of Surgical Oncology | Issue 7/2011

Login to get access

Abstract

Background

The Barcelona Clinic Liver Cancer (BCLC) staging system recommends first-line therapy for each tumor stage. We evaluated the effect of compliance with BCLC treatment allocation on the prognosis of patients with hepatocellular carcinoma (HCC).

Methods

We retrospectively analyzed 359 consecutive, newly diagnosed HCC patients treated in our Liver Unit during a 14-year period. For each stage, survival was compared according to whether treatment matched the BCLC recommendation. We also compared the survival of patients in the same BCLC stage who received different treatments, and patients in different BCLC stages receiving the same treatment.

Results

BCLC-A patients treated with radical therapies (66%) survived longer (117 vs. 20 months; p < 0.001) than patients (33%) who received locoregional or systemic therapies. Survival of BCLC-B patients treated with locoregional treatments (57%) was shorter (24 vs. 71 months; p < 0.001) than that of patients receiving radical therapies (32%). BCLC-C patients treated with systemic therapy or supportive care survived shorter (6 vs. 11 months; p = 0.003) than those receiving locoregional therapies (39%). Survival of BCLC-D patients receiving systemic therapies or supportive care was significantly lower than that of patients treated by liver transplantation (5 vs. 137 months; p < 0.001).

Conclusions

In addition to BCLC stage, actual treatment determines survival in patients with HCC.
Literature
1.
Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329–38.PubMedCrossRef
2.
Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48(Suppl 1):S20–37.PubMedCrossRef
3.
Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.PubMedCrossRef
4.
Ho MC, Huang GT, Tsang YM, Lee PH, Chen DS, Sheu JC, et al. Liver resection improves the survival of patients with multiple hepatocellular carcinomas. Ann Surg Oncol. 2009;16:848–55.PubMedCrossRef
5.
Chen CH, Hu FC, Huang GT, Lee PH, Tsang YM, Cheng AL, et al. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method—analysis of 2010 Taiwanese patients. Eur J Cancer. 2009;45:1630–9.PubMedCrossRef
6.
Vitale A, Saracino E, Boccagni P, Brolese A, D’Amico F, Gringeri E, et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc. 2009;41:1260–3.PubMedCrossRef
7.
Torzilli G, Donadon M, Marconi M, Palmisano A, Del Fabbro D, Spinelli A, et al. Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis. Arch Surg. 2008;143:1082–90.PubMedCrossRef
8.
Herrero JI, Sangro B, Pardo F, Quiroga J, Inarrairaegui M, Rotellar F, et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl. 2008;14:272–8.PubMedCrossRef
9.
Vauthey JN, Ribero D, Abdalla EK, Jonas S, Bharat A, Schumacher G, et al. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg. 2007;204:1016–27; discussion 1027–8.
10.
D’Avola D, Iñarrairaegui M, Bilbao JI, Martinez-Cuesta A, Alegre F, Herrero JI, et al. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology. 2009;56:1683–8.PubMed
11.
Kim KM, Kim JH, Park IS, Ko GY, Yoon HK, Sung KB, et al. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion. J Gastroenterol Hepatol. 2009;24:806–14.PubMedCrossRef
12.
Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71–81.PubMedCrossRef
13.
Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2006; 66: 792–800.PubMedCrossRef
14.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.PubMedCrossRef
15.
Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006;44:723–31.PubMedCrossRef
16.
Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707–16.PubMedCrossRef
17.
Camma C, Di Marco V, Cabibbo G, Latteri F, Sandonato L, Parisi P, et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther. 2008;28:62–75.PubMedCrossRef
18.
19.
Toso C, Kneteman NM, James Shapiro AM, Bigam DL. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int. 2009;22:869–75.PubMedCrossRef
20.
Yao FY. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008;8:1982–9.PubMedCrossRef
21.
Lai EC, Ng IO, Ng MM, Lok AS, Tam PC, Fan ST, et al. Long-term results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathological features. Hepatology. 1990;11:815–8.PubMedCrossRef
22.
Hanazaki K, Kajikawa S, Shimozawa N, Shimada K, Hiraguri M, Koide N, et al. Hepatic resection for large hepatocellular carcinoma. Am J Surg. 2001;181:347–53.PubMedCrossRef
23.
Cucchetti A, Ercolani G, Vivarelli M, Cescon M, Ravaioli M, Ramacciato G et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg. 2009;250:922–8.PubMedCrossRef
24.
Kiely JM, Rilling WS, Touzios JG, Hieb RA, Franco J, Saeian K, et al. Chemoembolization in patients at high risk: results and complications. J Vasc Interv Radiol. 2006;17:47–53.PubMedCrossRef
Metadata
Title
Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages
Authors
Delia D’Avola, MD
Mercedes Iñarrairaegui, MD, PhD
Fernando Pardo, MD
Fernando Rotellar, MD, PhD
Pablo Marti, MD
José I. Bilbao, MD, PhD
Antonio Martinez-Cuesta, MD
Alberto Benito, MD, PhD
Felix Alegre, MD
Erica Mauleón, MD
José I. Herrero, MD, PhD
Jorge Quiroga, MD, PhD
Jesus Prieto, MD, PhD
Bruno Sangro, MD, PhD
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1551-4

Other articles of this Issue 7/2011

Annals of Surgical Oncology 7/2011 Go to the issue

Reconstructive Oncology

Microsurgical Reconstruction of the Oral Cavity with Free Flaps from the Anterolateral Thigh and the Radial Forearm: A Comparison of Perioperative Data from 161 Cases

Healthcare Policy and Outcomes

Quality Improvement of Pancreatic Surgery by Centralization in the Western Part of the Netherlands

Breast Oncology

Poorer Survival Outcomes for Male Breast Cancer Compared with Female Breast Cancer May Be Attributable to In-Stage Migration

Hepatobiliary Tumors

Two-Stage Resection for Bilobar Colorectal Liver Metastases: R0 Resection Is the Key

Urologic Oncology

Dynamic Sentinel Node Biopsy for Inguinal Lymph Node Staging in Patients with Penile Cancer: A Systematic Review and Cumulative Analysis of the Literature

Colorectal Cancer

Outcome of Laparoscopic Resection for Colorectal Cancer in Patients with High Operative Risk